KLI

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea.

Metadata Downloads
Alternative Title
Korean J Intern Med. 2021 Jul;36(4):906-913.
Abstract
Background/aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study was to investigate the safety and effectiveness of rivaroxaban use in Korean patients with non-valvular AF in a real-world setting.

Methods: This was an analysis of the Korean patients in Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific (XANAP), which was a prospective, observational cohort study including patients with non-valvular AF starting rivaroxaban treatment to prevent stroke or non-central nervous system systemic embolism (non-CNS SE), conducted in 10 Asian countries.

Results: A total of 844 patients were enrolled in the Korean portion of the XANAP study. In XANAP Korea, the mean age was 70.1 years and 62.6% were males. The mean CHADS2 score was 2.5 and the mean CHA2DS2-VASc score was 3.8. 47% of the patients had experienced prior stroke or non-CNS SE or transient ischemic attack. 73.6% of the patients had CHADS2 score ≥ 2. Incidence proportions of 0.8% of the patients (1.1 per 100 patient-years) developed adjudicated treatment-emergent major bleeding. Death was observed in 1.2% of the patients. The incidence of non-major bleeding as well as thromboembolic event were 8.4% (11.6 per 100 patient-years) and 1.5% (2.0 per 100 patient-years), respectively.

Conclusion: This study reaffirmed the consistent safety profile of rivaroxaban. We found consistent results with overall XANAP population for rivaroxaban in terms of safety in non-valvular AF patients for the prevention of stroke and non-CNS SE.

Keywords: Atrial fibrillation; Korea; Rivaroxaban; Stroke.
Author(s)
권순억김남호김영훈남기병라승원라종호박형욱신동구심재민온영근이문형홍근식Pierre Amarenco
Issued Date
2021
Type
Article
Keyword
Atrial fibrillationKoreaRivaroxabanStroke
DOI
10.3904/kjim.2020.217
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7214
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_kiss_primary_3891127&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,A%20prospective,%20observational%20study%20of%20rivaroxaban%20for%20stroke%20prevention%20in%20atrial%20fibrillation:%20the%20XANAP%20Korea.&offset=0&pcAvailability=true
Publisher
Korean Journal of Internal Medicine
Location
대한민국
Language
한국어
ISSN
1226-3303
Citation Volume
36
Citation Number
4
Citation Start Page
906
Citation End Page
913
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.